Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
October 09, 2023 08:04 ET
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
May 14, 2020 07:05 ET
|
Cocrystal Pharma, Inc.
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses
October 08, 2019 09:15 ET
|
Cocrystal Pharma, Inc.
- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design platform...
Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses
October 01, 2019 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
May 20, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest...
Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
January 22, 2019 08:00 ET
|
Cocrystal Pharma, Inc.
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination...
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
October 08, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 09, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...